Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an ...

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast ...

A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for ...

The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s ...

Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used ...

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve ...